anti-CD5 γδ CAR-T therapy / Curocell - LARVOL DELTA

Curocell announces preclinical research results for ‘gamma delta CAR-T treatment’ at SITC in the U.S. [Google translation] (HIT News) - "Curocell...announced 'gamma delta (γδ)' for T-cell lymphoma at the '2023 American Society for Immunotherapy of Cancer (SITC 2023)' on the 4th (local time). ) announced the preclinical results of ‘CAR-T treatment’....At this conference, Curocell disclosed the details of its research on CD5-targeted allogeneic gamma delta CAR-T treatment for the treatment of T-cell lymphoma."

Preclinical • Hematological Malignancies • Lymphoma • Oncology

Preclinical assessment of allogeneic Anti-CD5 γδ CAR-T therapy for T-Cell malignancies (SITC 2023) - "Interestingly, in the context of αβ T cells, C7 αβCAR5 showed higher cell expansion and greater anti-tumor effect than A7 αβCAR5, implying that the exhaustion of A2 CAR5 is more severe in the context of αβ T cells, compared to γδ T cells. Conclusions Our successful generation and evaluation of anti-CD5 γδ CAR T cells provide the foundation for developing allogeneic CAR T cell therapy as a promising treatment of T cell malignancies."

Preclinical • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma